NCT01479530View on ClinicalTrials.gov

Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

PHASE3CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Parkinson's Disease
Interventions
DRUG

Placebo

Once daily; tablet; orally; 16 weeks

DRUG

Azilect®

1 mg daily; tablet; orally; 16 weeks

Trial Locations (18)

100034

CN015, Beijing

100050

CN008, Beijing

CN017, Beijing

100730

CN001, Beijing

CN018, Beijing

200025

CN012, Shanghai

200040

CN007, Shanghai

200127

CN013, Shanghai

215004

CN006, Suzhou

310009

CN004, Hangzhou

430022

CN009, Wuhan

510120

CN003, Guangzhou

510180

CN005, Guangzhou

510260

CN019, Qingyu Zhou

CN020, Qingyu Zhou

610041

CN011, Chengdu

710032

CN010, Xi'an

710061

CN014, Zi’an

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT01479530 - Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China | Biotech Hunter | Biotech Hunter